Mereo BioPharma Group plc MREO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Mereo BioPharma Group plc (MREO) is a healthcare company listed in the US with a market value of about $49M. In fiscal year 2025 it had revenue of $500000 and net income of -$42M, a net margin of -8375.6%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -65%.
About Mereo BioPharma Group
Mereo BioPharma Group is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $49M in 2021 to $500000 in 2025, a decline of about 68.2% a year. It was profitable in 1 of the last 10 years in our data. It spends 3553% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500000 | $0 | $10M | $0 | $49M | — | — | — | — | — |
| Net income | -$42M | -$43M | -$29M | -$42M | $17M | -$223M | -$46M | -$41M | -$52M | -$35M |
| Free cash flow | -$31M | -$33M | -$21M | -$49M | -$8M | -$39M | -$61M | -$30M | -$43M | -$37M |
| EPS (diluted) | $-0.26 | $-0.27 | $-0.18 | $-0.26 | $0.11 | $-1.40 | $-0.29 | $-0.26 | $-0.33 | $-0.22 |
| Net margin | -8375.6% | — | -294.7% | — | 34.9% | — | — | — | — | — |
| ROIC | -97.5% | -70.3% | -53.6% | -80.1% | -22.6% | -3153.9% | -55.1% | -54.6% | -45.0% | -38.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Mereo BioPharma Group pay a dividend?
Not currently.
Is Mereo BioPharma Group a good stock to buy?
We do not give buy or sell advice. Mereo BioPharma Group scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.